Txog C-CAR031

C-CAR031 yog kev kho mob autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T), uas tab tom kawm rau kev kho mob HCC.

Cov kev tshawb fawb txog kev nce qib ntawm C-CAR031 hauv hepatocellular carcinoma (HCC) tau nthuav tawm hauv kev hais lus ntawm lub rooj sib tham txhua xyoo ntawm American Society of Clinical Oncology (ASCO) uas tau muaj nyob hauv Chicago xyoo 2024.

Cov Txheej Txheem: Qhov kev sim tshuaj thawj zaug hauv tib neeg, qhib daim ntawv lo rau kev nce koob tshuaj siv kev tsim qauv titration ntxiv rau i3 + 3. GPC3 + ​​cov neeg mob HCC siab heev uas tsis ua tiav ≥ 1 kab kev kho mob tau txais ib qho iv infusion ntawm C-CAR031 tom qab tus qauv lymphodepletion. Cov ntsiab lus tseem ceeb yog kev nyab xeeb thiab kev kam rau siab, lwm yam suav nrog pharmacokinetics thiab kev ua tau zoo ua ntej. Cov xwm txheej tsis zoo (AEs) tau raug ntsuas los ntawm CTCAE 5.0, thiab cytokine release syndrome (CRS) / immune effector cell-associated neurotoxicity syndrome (ICANS) tau raug soj ntsuam raws li ASTCT 2019 cov qauv. Cov lus teb tau raug soj ntsuam los ntawm tus kws tshawb nrhiav raws li RECIST 1.1.

Cov Txiaj Ntsig: Txij li Lub Ib Hlis 5, 2024, tag nrho ntawm 24 pts tau txais C-CAR031 infusion ntawm 4 koob tshuaj (DLs). Tag nrho cov pts muaj BCLC theem C HCC, 83.3% (20/24) muaj extrahepatic metastasis. Tus lej nruab nrab ntawm cov kab kev kho mob yav dhau los yog 3.5 (ntau yam 1-6), 23 (95.8%) pts tau txais ICIs (immune checkpoint inhibitors) thiab TKIs (tyrosine kinase inhibitors). Tag nrho cov pts tau soj ntsuam rau kev nyab xeeb. Tsis muaj tshuaj lom uas txwv tsis pub noj tshuaj thiab ICANS tau pom. CRS tau pom hauv 22 (91.7%) pts nrog tsuas yog 1 (4.2%) qib (G) 3 CRS. Cov ≥G3 AEs feem ntau yog lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) thiab transaminase elevation (16.7%). Ib qho pt (4.2%) muaj G4 myelosuppression thiab 1 pt (4.2%) muaj G3 interstitial pneumonitis ntawm DL4 los ntawm G3 CRS. Tag nrho cov AEs yog rov qab tau. 22 pts tau soj ntsuam rau qhov ua tau zoo. Kev txo qis ntawm cov qog tau pom hauv 90.9% pts, tsis yog tsuas yog hauv cov qhov txhab intrahepatic tab sis kuj tseem muaj extrahepatic nrog qhov nruab nrab txo qis ntawm 44.0% (ntau yam, 3.4% -94.4%). Tus nqi tswj kab mob yog 90.9% thiab tus nqi teb lub hom phiaj (ORR) yog 50.0% rau pts ntawm txhua DLs. Hauv DL4, ORR yog 57.1%.

Xaus Lus: Txoj kev tshawb fawb no tau qhia txog kev nyab xeeb uas tswj tau thiab txhawb kom muaj kev ua haujlwm tiv thaiv qog ntawm C-CAR031 hauv cov neeg mob HCC uas tau kho mob hnyav.

Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.

Xov Tooj: 4008803716

Email：myimmnet@163.com

Cov ntaub ntawv siv los ua piv txwv

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)